
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc. demonstrates a strong positive outlook due to its proprietary Native Complex Platform, which has the potential to significantly enhance the development of G protein-coupled receptor (GPCR) therapies, particularly in areas of endocrinology, immunology, and metabolic disease. The company’s management expresses confidence in its ability to execute Phase 1 trials more efficiently with its candidate SEP-786, backed by improved preclinical testing and a potentially superior pharmacokinetic profile compared to previous iterations. Additionally, promising results from TPTx rat models indicate that SEP-479 effectively restores calcium/phosphate balance, showcasing the therapeutic potential of its current pipeline.
Bears say
Septerna Inc. is experiencing challenges that contribute to a negative outlook on its stock, particularly related to its clinical-stage pipeline, which has yet to deliver commercially viable products despite its innovative approach to G protein-coupled receptor (GPCR) drug discovery. The company is heavily reliant on the success of its proprietary Native Complex Platform, which is still unproven in generating revenue, raising concerns about the long-term sustainability of its financial health. Additionally, the therapeutic areas targeted, such as endocrinology and immunology, face significant competition and regulatory hurdles, which may impede the development timelines and market entry of its product candidates.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares